ReviewNature reviews. Nephrology2012
Monocyte subpopulations and cardiovascular risk in chronic kidney disease.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04238338 (Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients), which is not on this map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients
Who cites it
88 citing papers in PubMed, 162 citations in OpenAlex.
- Intradialytic cycling does not exacerbate microparticles or circulating markers of systemic inflammation in haemodialysis patients.European journal of applied physiology · 2022Trial
- Exercise during hemodialysis does not affect the phenotype or prothrombotic nature of microparticles but alters their proinflammatory function.Physiological reports · 2018Trial
- Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation.Frontiers in immunology · 2018Trial
- Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy.International journal of molecular sciences · 2026Review
- Distinct immunometabolic signatures in peripheral blood mononuclear cells are linked to systemic inflammation in type 2 diabetes and diabetic kidney disease.Molecular biomedicine · 2026Article
- Construction of a C-reactive protein-albumin-lymphocyte index-based prediction model for all-cause mortality in patients on maintenance hemodialysis.Renal failure · 2025Article
- Skeletal muscle density mediates the relationships of monocyte-lymphocyte ratio, apolipoprotein A1/HDL, and alkaline phosphatase with thoracic aortic calcification: a multicenter study in patients undergoing maintenance dialysis.Lipids in health and disease · 2025Article
- An Immuno-Fragile Profile Is Associated with Mortality Risk in Patients with Chronic Kidney Disease.Biomedicines · 2025Article
- Trained immunity: from kidney failure to organ transplantation.Nature reviews. Nephrology · 2025Article
- Platelet-Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Monocyte human leukocyte antigen-DR-mediated diabetic nephropathy progression is a promising therapeutic target.Frontiers in endocrinology · 2025Article
- Monocyte/Macrophage-Specific Loss of ARNTL Suppresses Chronic Kidney Disease-Associated Cardiac Impairment.International journal of molecular sciences · 2024Article
- Inflammatory indexes and anemia in chronic kidney disease: correlation and survival analysis of the National Health and Nutrition Examination Survey 2005-2018.Renal failure · 2024Article
- Automated, Point-of-Care mobile flow cytometry: Bringing the laboratory to the sample.Heliyon · 2024Article
- Threshold-modifying effect of the systemic inflammatory response index on kidney function decline in hypertensive patients.European journal of medical research · 2024Article
- Novel T-cell subsets as non-invasive biomarkers of vascular damage along the predialysis stages of chronic kidney disease.Frontiers in medicine · 2024Article
- Exploring the causal relationship between immune cell and all-cause heart failure: a Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- Modulation of monocyte subtypes in diabetes after non-surgical periodontal treatment.Clinical oral investigations · 2023Article
- Leukocyte-endothelial interaction in CKD.Clinical kidney journal · 2023Review
- Successful Management of Critical Acute Respiratory Distress Syndrome following COVID-19 through Extracorporeal Membrane Oxygenation in a Patient with Concurrent Nephrotic Syndrome Relapse.Internal medicine (Tokyo, Japan) · 2023Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic microinflammation and its cellular hallmark, monocyte activation, contribute substantially to the tremendous burden of cardiovascular disease (CVD) in patients with chronic kidney diseases (CKD). Monocyte heterogeneity is widely acknowledged. Cell-surface expression of CD14 and CD16 defines three functionally and phenotypically distinct subsets of monocytes: classical (CD14(++)CD16(-)) monocytes, intermediate (CD14(++)CD16(+)) monocytes, and nonclassical (CD14(+)CD16(++)) monocytes. A growing body of circumstantial evidence suggests that intermediate monocytes, in particular, contribute to the development of atherosclerosis in the general population as well as in patients with CKD. Intermediate monocytes express a unique pattern of chemokine receptors that have been implicated in atherogenesis. Moreover, this subset of monocytes is predisposed to secrete proinflammatory cytokines. Findings from epidemiological studies indicate that numbers of intermediate monocytes increase with worsening renal function, and that high cell counts predict adverse outcomes in patients undergoing dialysis as well as in patients at early stages of CKD. Based on laboratory and clinical data, intermediate monocytes are a promising therapeutic target for CVD in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.